Search

Your search keyword '"Langlais, Alexandra"' showing total 385 results

Search Constraints

Start Over You searched for: Author "Langlais, Alexandra" Remove constraint Author: "Langlais, Alexandra"
385 results on '"Langlais, Alexandra"'

Search Results

1. What Place for Contractual Commitments in the Protection of European Agricultural Soils? The Example of Carbon Sequestration

3. Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer

4. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial

6. Main conclusions and perspectives from the collective scientific assessment of the effects of plant protection products on biodiversity and ecosystem services along the land–sea continuum in France and French overseas territories

8. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

9. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial

10. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial

13. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)

14. Editorial

15. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

16. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

17. Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

18. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

19. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

20. What place for contractual commitments in the protection of European agricultural soils? The example of carbon sequestration

22. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

23. Le droit de l'environnement, caution de la dimension agroécologique de la PAC 2023 ?

24. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques

25. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

27. Paysage

28. Ecosystème

30. Introduction

33. A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT ‐0701 MAPS phase 3 trial

34. Géoingénierie

35. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques. Rapport d'ESCo

36. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques- Résumé de l'Expertise scientifique collective - Mai 2022

37. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques - Synthèse de l'Expertise scientifique collective - Mai 2022

38. Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort

39. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

40. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques. Rapport de l’expertise scientifique collective

41. Le futur 8ème programme d'action général pour l'environnement in chronique annuelle droit de l'environnement de l'Union européenne coordonnée par Nathalie Hervé-Fournereau

42. Géoingénierie

43. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques. Rapport de l’expertise scientifique collective

44. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques. Rapport d'ESCo

45. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques - Synthèse de l'Expertise scientifique collective - Mai 2022

46. Impacts des produits phytopharmaceutiques sur la biodiversité et les services écosystémiques. Synthèse de l’expertise scientifique collective

47. Chronique annuelle Droit de l'environnement de l'Union européenne - coordination N. Hervé-Fournereau

48. Les services écosystémiques pour penser la qualité des sols ? Réflexions juridiques relatives à la qualité des sols agricoles

49. Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

50. Trajectoires socio-écologiques des IAE et politiques publiques ou comment favoriser durablement la multifonctionnalité des paysages ?

Catalog

Books, media, physical & digital resources